Federal Register Final Rule: Medicare Program; Extending the Medicare Diabetes Prevention Program's (MDPP) Expanded Model Emergency Policy Through CY 2023
Policy FR-2023-09188 · Endocrinology
HighThe extension of in-person delivery flexibility for the MDPP until December 31, 2023, allows suppliers to adapt their services during ongoing transitions from the Public Health Emergency. This policy
View alertLCD L33431: HbA1c — Palmetto GBA
Policy LCD-L33431 · Endocrinology
HighThe new LCD for HbA1c testing could significantly alter billing practices for diabetes management, especially with Palmetto GBA as the contractor. Providers may need to adjust their coding and documen
View alertLCD L38686: Implantable Continuous Glucose Monitors (I-CGM) — WPS
Policy LCD-L38686 · Endocrinology
HighThe implementation of the new LCD for Implantable Continuous Glucose Monitors (I-CGM) by WPS may affect billing processes for diabetes management services. Providers will need to familiarize themselve
View alertLCD L36864: GlycoMark® Testing for Glycemic Control — Noridian
Policy LCD-L36864 · Endocrinology
HighThe implementation of GlycoMark® testing for glycemic control represents a significant change in billing practices, particularly for outpatient services. This may lead to supports compliance with updated rates oppor
View alert